Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
3 INNOVATION
177Lu-PSMA-617 reduced risk of death by 38%, and radiographic
progression or death by 60% in patients with mCRPC (VISION)
Presented at ASCO 2021
OS HR1: 0.62 (95%CI: 0.52, 0.74)
Median OS: 15.3 months (14.2, 16.9)³ vs. 11.3 (9.8, 13.5)³
100
90
80
Event-free probability (%)
288
70
60
50
rPFS HR1: 0.40 (99.2%CI: 0.29, 0.57)
Median rPFS: 8.7 months (7.9, 10.8)2 vs. 3.4 (2.4, 4.0)²
100
90
Event-free probability (%)
80
70
60
50
40
30
40
30
20
20
10
177 Lu-PSMA-617+ BSOC (n=551)
10
177 Lu-PSMA-617+ BSOC (n=385)
BSOC Only (n=280)
BSOC Only (n=196)
0
0
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
0
1 2 3 4 5
Time from randomization (months)
Number still at Risk
177 Lu-PSMA-617
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Time from randomization (months)
Number still at Risk
551 535
506 470 425 377 332 289 236 166 112 63
36
15
5
2
0
177 Lu-PSMA-617
+ BSOC
+ BSOC
33 16
6
2
0
0
0
385 373 362 292 272 235 215 194 182 146 137 121 88 83 71 51 49 37 21 18 6 1 1 0
BSOC Only 196 146 119 58 36 26 19 14 14 13 13 11 7 7 7 4 3 3 2
2
0
0 0 0
◉
■
☐
BSOC Only 280 238 203 173 155 133 117 98 73 51
Regulatory submissions in US and EU on track for H2 2021
Data support investigating 177 Lu-PSMA-617 in earlier lines of therapy
Two Ph3 studies in pre-taxane 1L/2L mCRPC PSMAfore and mHSPC PSMAddition already underway
1. p<0.001, stratified log-rank test 1-sided. 2.99.2% CI, in line with hypothesis testing strategy. 3. 95% CI.
12 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation